Wolff Wiese Magana LLC Makes New $59,000 Investment in Jasper Therapeutics, Inc. (NASDAQ:JSPR)

Wolff Wiese Magana LLC bought a new stake in Jasper Therapeutics, Inc. (NASDAQ:JSPR) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 3,146 shares of the company’s stock, valued at approximately $59,000.

Several other hedge funds and other institutional investors have also modified their holdings of the business. Virtu Financial LLC purchased a new stake in shares of Jasper Therapeutics in the first quarter worth approximately $306,000. Rhumbline Advisers acquired a new stake in shares of Jasper Therapeutics during the 2nd quarter valued at $300,000. American Century Companies Inc. grew its holdings in shares of Jasper Therapeutics by 27.1% during the 2nd quarter. American Century Companies Inc. now owns 14,204 shares of the company’s stock valued at $322,000 after acquiring an additional 3,032 shares in the last quarter. Concurrent Investment Advisors LLC acquired a new position in shares of Jasper Therapeutics in the first quarter worth $599,000. Finally, Bank of New York Mellon Corp purchased a new stake in shares of Jasper Therapeutics during the second quarter worth $740,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have commented on JSPR. Stifel Nicolaus began coverage on Jasper Therapeutics in a research note on Thursday, June 27th. They issued a “buy” rating and a $86.00 target price on the stock. Evercore ISI reissued an “outperform” rating and issued a $65.00 price target on shares of Jasper Therapeutics in a research note on Monday, August 26th. BTIG Research started coverage on shares of Jasper Therapeutics in a research report on Monday, July 8th. They set a “buy” rating and a $90.00 price objective on the stock. HC Wainwright reissued a “buy” rating and issued a $65.00 target price on shares of Jasper Therapeutics in a research report on Tuesday. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Jasper Therapeutics in a report on Monday, September 9th. Ten investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average target price of $74.86.

Jasper Therapeutics Stock Down 0.5 %

NASDAQ:JSPR opened at $18.18 on Thursday. The company’s 50 day moving average is $19.00 and its 200-day moving average is $21.51. Jasper Therapeutics, Inc. has a 12 month low of $4.00 and a 12 month high of $31.01. The firm has a market cap of $273.86 million, a price-to-earnings ratio of -3.23 and a beta of 2.21.

Jasper Therapeutics (NASDAQ:JSPR) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.97) EPS for the quarter, topping the consensus estimate of ($1.09) by $0.12. Research analysts predict that Jasper Therapeutics, Inc. will post -4.16 EPS for the current fiscal year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc, a clinical-stage biotechnology company, develops therapeutic agents for hematopoietic stem cell transplantation and gene therapies. The company's lead product candidate is briquilimab, which is in clinical development as a novel therapeutic antibody that clears hematopoietic stem cells from bone marrow in patients prior to undergoing allogeneic stem cell therapy or stem cell gene therapy.